Sanofi Pasteur's dengue vaccine demonstrates proof of efficacy
Sanofi Pasteur, the vaccines division of Sanofi, announced that its tetravalent dengue vaccine candidate demonstrated proof of efficacy against dengue, a threat to almost 3 billion people, in the world's first ever dengue efficacy trial conducted in Thailand, with excellent safety.
The global burden of dengue infection is more than triple current estimates from the World Health Organization, according to a multinational study published today in the journal 'Nature'.